Financial Performance - The company's revenue for Q3 2023 was ¥89,151,674.77, a decrease of 49.42% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2023 was ¥3,657,889.40, down 93.40% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥116,850.09, a decrease of 99.77% compared to the previous year[5]. - Total operating revenue for Q3 2023 reached CNY 746,127,863.80, a significant increase of 76.5% compared to CNY 422,920,517.10 in the same period last year[25]. - Net profit for Q3 2023 was CNY 313,190,833.52, up 186.5% from CNY 109,484,923.35 in Q3 2022[26]. - Operating profit for the period was CNY 381,896,140.21, compared to CNY 128,739,862.36 in the previous year, reflecting a growth of 195.5%[26]. - Basic earnings per share for Q3 2023 were CNY 2.49, compared to CNY 0.87 in Q3 2022, representing a growth of 186.2%[27]. Assets and Liabilities - Total assets as of September 30, 2023, were ¥1,861,731,324.57, an increase of 1.00% from the end of the previous year[5]. - Total assets as of Q3 2023 amounted to CNY 1,861,731,324.57, slightly up from CNY 1,843,255,720.64 at the end of the previous year[23]. - Total liabilities decreased to CNY 189,889,198.55 from CNY 466,886,029.71, indicating a reduction of 59.4%[23]. - Total current assets decreased to CNY 916,161,811.86 from CNY 1,014,005,861.36[21]. - Fixed assets decreased to CNY 462,042,664.85 from CNY 479,786,407.35[21]. - Long-term equity investments remained stable at CNY 1,451,008.96[21]. Cash Flow - Operating cash flow for the year-to-date was ¥52,591,592.89, a decrease of 18.57%[5]. - Cash flow from operating activities was CNY 514,413,371.61, an increase from CNY 310,048,077.00 in the same quarter last year[29]. - The net cash flow from operating activities for Q3 2023 was ¥52,591,592.89, a decrease of 18.5% compared to ¥64,584,440.06 in Q3 2022[30]. - Total cash inflow from investment activities reached ¥1,241,331,779.53, significantly up from ¥514,151,481.94 in the same period last year, marking an increase of 141.5%[30]. - The net cash flow from investment activities was ¥25,532,994.27, recovering from a negative cash flow of -¥71,628,179.98 in Q3 2022[30]. - Cash and cash equivalents at the end of Q3 2023 totaled ¥288,778,223.22, compared to ¥226,440,815.64 at the end of Q3 2022, reflecting an increase of 27.5%[31]. - The total cash outflow from financing activities was ¥90,696,527.78, slightly higher than ¥81,746,173.48 in Q3 2022[31]. - The company reported a net cash flow from financing activities of -¥90,696,527.78, compared to -¥1,746,173.48 in the same quarter last year[31]. Shareholder Information - The number of common shareholders at the end of the reporting period was 26,884[16]. - The largest shareholder, Yang Xining, holds 27.34% of the shares, totaling 34,446,500 shares[16]. Research and Development - Research and development expenses for the first nine months of 2023 were ¥34,942,697.26, an increase of 83.58% year-on-year, reflecting increased investment in R&D[11]. - Research and development expenses increased to CNY 34,942,697.26, up 83.3% from CNY 19,034,128.86 year-on-year[25]. Taxation - The income tax expense for the first nine months of 2023 increased by 267.70% to ¥66,424,275.94, attributed to higher profits[11]. - The company's cash flow from tax payments was ¥260,407,775.36, a significant increase from ¥45,414,812.74 in the same quarter last year, reflecting a rise of 474.5%[30]. Investment Activities - Cash received from investment increased by 142.16% to CNY 1,235,000,000 compared to CNY 510,000,000 in the previous period[14]. - Cash paid for the acquisition of fixed assets and intangible assets rose by 124.73% to CNY 169,398,785 from CNY 75,379,661[14]. - Cash paid for investment increased by 105.02% to CNY 1,046,400,000 compared to CNY 510,400,000 in the previous period[14]. - Cash paid for dividends and interest increased by 236.89% to CNY 50,696,527 from CNY 15,048,481[14]. Inventory - The company reported a significant increase in accounts receivable, which rose by 369.79% to ¥197,512,464.51 due to increased sales[9]. - Inventory increased to CNY 256,247,113.92 from CNY 241,138,563.67[21].
拓新药业(301089) - 2023 Q3 - 季度财报